Posts

EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer

The EMA's CHMP has recommended approval of a combination therapy of BMS's Opdivo...

AHA 2024: Tirzepatide improves outcomes for major heart...

Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide a...

CHMP recommends AstraZeneca’s Tagrisso for EU approval ...

EMA's CHMP has recommended AstraZeneca's Tagrisso for approval in the European U...

AstraZeneca picks first Treg cell therapy from Quell Th...

AstraZeneca will advance preclinical and clinical development of the Type 1 Diab...

Intellia’s gene editing therapy shows early potential i...

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American...

Sandoz’s Afqlir gains EC marketing authorisation for re...

The EC has granted marketing authorisation for Sandoz's Afqlir for the treatment...

AbbVie’s Elahere wins European approval for certain ova...

The decision in Europe follows an approval granted by the US Food and Drug Admin...

FDA approves Syndax’s Revuforj to treat leukaemia

The US FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treatin...

FDA reviews Sanofi and Regeneron’s Dupixent label expan...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use...

AC Immune’s stock jumps after Parkinson’s therapy shows...

AC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following...

FDA approves Azurity Pharmaceuticals’ Danziten for CML ...

The US Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ ...

Bavarian Nordic shares sink by 12% after mpox sales slu...

Revenue for the mpox vaccine is down compared to last year however its travel va...

FDA to lift hold over Novavax flu-shot program

Maryland-based biotech Novavax experienced a clinical hold on its late-stage tri...

J&J MedTech Gets FDA Nod for Varipulse PFA System

After the FDA approves Johnson & Johnson MedTech’s Varipulse technology for the ...

Bad News for AbbVie as Emraclidine Fails to Perform in ...

AbbVie saw its valuation drop by around $40 billion following disappointing resu...

Kronos mulls ‘strategic alternatives’ after axing cance...

The company has discontinued the Phase I/II trial of its only clinical candidate...